<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02547831</url>
  </required_header>
  <id_info>
    <org_study_id>INT 13/12</org_study_id>
    <nct_id>NCT02547831</nct_id>
  </id_info>
  <brief_title>Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients</brief_title>
  <official_title>Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministero della Salute, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter observational study under the umbrella of the ISG (Italian&#xD;
      Sarcoma Group) evaluating local progression-free survival at 3 years of patients affected by&#xD;
      extra-abdominal primary fibromatosis managed with front-line conservative approach and&#xD;
      treated only in case of demonstrated progressive disease.&#xD;
&#xD;
      All patients included will be placed on wait and see approach and then shifted to treatment&#xD;
      in case of documented radiological progressive disease.&#xD;
&#xD;
      For patient primarily evaluated for suspected desmoid tumor, a core-needle biopsy (eventually&#xD;
      under CT/ultrasound guide) will be obtained for histological diagnosis and mutational&#xD;
      analysis of CTNNB1 exon 3 (gene encoding Beta-catenin). If incisional biopsy or surgical&#xD;
      procedure has done elsewhere, samples will be requested for histological confirmation and&#xD;
      mutational analysis (centralization at the investigators Institution).&#xD;
&#xD;
      In case of progression at 3 months, defined as tumor growth documented radiologically (by&#xD;
      contrast enhanced MRI) by Response Evaluation Criteria in Solid Tumors (RECIST), administered&#xD;
      treatments will be proposed and then registered in the clinical database.The choice of the&#xD;
      treatment and eventually the possibility of continuation of &quot; surveillance only&quot; will be at&#xD;
      the discretion of Institution's Multidisciplinary Sarcoma Committee or as part of clinical&#xD;
      trials with the consent of patient.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter observational study under the umbrella of the ISG (Italian&#xD;
      Sarcoma Group) evaluating local progression-free survival at 3 years of patients affected by&#xD;
      extra-abdominal primary fibromatosis managed with front-line conservative approach and&#xD;
      treated only in case of demonstrated progressive disease.&#xD;
&#xD;
      All patients included will be placed on wait and see approach and then shifted to treatment&#xD;
      in case of documented radiological progressive disease.&#xD;
&#xD;
      For patient primarily evaluated for suspected desmoid tumor, a core-needle biopsy (eventually&#xD;
      under CT/ultrasound guide) will be obtained for histological diagnosis and mutational&#xD;
      analysis of CTNNB1 exon 3 (gene encoding Beta-catenin). If incisional biopsy or surgical&#xD;
      procedure has done elsewhere, samples will be requested for histological confirmation and&#xD;
      mutational analysis (centralization at our Institution) and in selected cases a new biopsy&#xD;
      will be obtained.&#xD;
&#xD;
      In case of progression at 3 months, defined as tumor growth documented radiologically (by&#xD;
      contrast enhanced MRI) by Response Evaluation Criteria in Solid Tumors (RECIST), administered&#xD;
      treatments will be proposed and then registered in the clinical database (radiological&#xD;
      evaluation will be centralized at Istituto Rizzoli, Bologna- Dr. Vandel).&#xD;
&#xD;
      Therapy will include the following options:&#xD;
&#xD;
        -  Surgery&#xD;
&#xD;
        -  Radiotherapy&#xD;
&#xD;
        -  Medical treatment including hormonal therapy (e.g., tamoxifen, toremifene), low-dose&#xD;
           chemotherapy (e.g.,methotrexate and vinorelbine/vinblastine), NSAIDs (e.g., celecoxib),&#xD;
           and target therapy (Glivec)&#xD;
&#xD;
        -  Combination The choice of the treatment and eventually the possibility of continuation&#xD;
           of &quot; surveillance only&quot; will be at the discretion of Institution's Multidisciplinary&#xD;
           Sarcoma Committee or as part of clinical trials with the consent of patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Desmoid-type Fibromatosis</condition>
  <arm_group>
    <arm_group_label>Observational approach</arm_group_label>
    <description>Patients will be placed on wait and see approach and then shifted to specific treatment in case of progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational approach</intervention_name>
    <description>Patients will be placed under wait and see approach without any specific treatment</description>
    <arm_group_label>Observational approach</arm_group_label>
    <other_name>Wait and see approach</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients affected by extra-abdominal primary fibromatosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sporadic forms&#xD;
&#xD;
          -  No age limit (pediatric patients can be included)&#xD;
&#xD;
          -  Extra abdominal fibromatosis primary or with previous inadequate resection (R2) of the&#xD;
             extremities, chest/abdominal wall and head/neck&#xD;
&#xD;
          -  Histological diagnosis according to the WHO criteria done on biopsy or surgical&#xD;
             specimen by our pathologist&#xD;
&#xD;
          -  Diagnostic radiological exam performed (contrast enhanced MRI- T1 and T2 weighted)&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
          -  Adequate compliance of the patients to the plan of follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Controindication to MRI&#xD;
&#xD;
          -  Familial-type desmoid&#xD;
&#xD;
          -  Recurrence&#xD;
&#xD;
          -  Extraabdominal primary fibromatosis resected with R0/R1 margins&#xD;
&#xD;
          -  Patients on treatment for desmoid tumor&#xD;
&#xD;
          -  Other malignancies within past 5 years, with exception of carcinoma in situ of cervix&#xD;
             and basocellular skin cancers treated with eradicating intent&#xD;
&#xD;
          -  Serious psychiatric disease that precludes informed consent or limits compliance&#xD;
&#xD;
          -  Medical disease requesting treatment corresponding to one of the drugs currently use&#xD;
             in desmoid tumor [hormonal therapy (e.g., tamoxifen/toremifene, low-dose chemotherapy&#xD;
             (e.g., methotrexate and vinorelbine/vinblastine), NSAIDs (e.g., celecoxib), and target&#xD;
             therapy (Glivec)]&#xD;
&#xD;
          -  Impossibility to ensure adequate follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandro Gronchi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Istituto Tumori Milano</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alessandro Gronchi, MD</last_name>
    <phone>+390223903234</phone>
    <email>alessandro.gronchi@istitutotumori.mi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chiara Colombo, MD</last_name>
    <phone>+390223903234</phone>
    <email>chiara.colombo@istitutotumori.mi.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondazione del Piemonte per l' Oncologia - IRCCS</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Grignani, MD</last_name>
      <phone>+39.011.9933623</phone>
      <email>giovanni.grignani@ircc.it</email>
    </contact>
    <contact_backup>
      <last_name>Erica Palesandro</last_name>
      <phone>+39.011.9933623</phone>
      <email>erica.palesandro@ircc.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Tumori Milano</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Gronchi, MD</last_name>
      <phone>+39023903234</phone>
      <email>alessandro.gronchi@istitutotumori.mi.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>January 28, 2015</study_first_submitted>
  <study_first_submitted_qc>September 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <last_update_submitted>September 10, 2015</last_update_submitted>
  <last_update_submitted_qc>September 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromatosis, Aggressive</mesh_term>
    <mesh_term>Fibroma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

